TSHA Taysha Gene Therapies Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TSHA

Price (delayed)

$5.9

Market cap

$1.7B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.38

Enterprise value

$1.48B

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 23

Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to ...

Highlights
Taysha Gene Therapies's quick ratio has surged by 163% YoY and by 14% QoQ
Taysha Gene Therapies's revenue has decreased by 24% QoQ but it has increased by 3.4% YoY
The gross profit has decreased by 24% QoQ but it has increased by 3.4% YoY
Taysha Gene Therapies's net income has decreased by 50% YoY and by 19% QoQ
The company's equity fell by 14% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://tayshagtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of TSHA

TSHA stock price

How has the Taysha Gene Therapies stock price performed over time
Intraday
6.31%
1 week
-0.34%
1 month
-11.14%
1 year
111.47%
YTD
7.27%
QTD
31.99%

Financial performance

How have Taysha Gene Therapies's revenue and profit performed over time
Revenue
$7.47M
Gross profit
$7.47M
Operating income
-$132.56M
Net income
-$129.88M
Gross margin
100%
Net margin
-1,738.4%
TSHA's operating margin has shrunk by 57% QoQ and by 45% YoY
The net margin has plunged by 56% from the previous quarter and by 45% YoY
Taysha Gene Therapies's net income has decreased by 50% YoY and by 19% QoQ
The operating income has declined by 50% year-on-year and by 20% since the previous quarter

Price vs fundamentals

How does TSHA's price correlate with its fundamentals

Growth

What is Taysha Gene Therapies's growth rate over time

Valuation

What is Taysha Gene Therapies stock price valuation
TSHA P/E details
P/E
N/A
P/B
8
P/S
289.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
198.48
Taysha Gene Therapies's EPS has decreased by 12% QoQ and by 12% YoY
TSHA's price to book (P/B) is 63% higher than its last 4 quarters average of 4.6 but 45% lower than its 5-year quarterly average of 13.6
The company's equity fell by 14% QoQ
TSHA's price to sales (P/S) is 63% more than its last 4 quarters average of 166.8
Taysha Gene Therapies's revenue has decreased by 24% QoQ but it has increased by 3.4% YoY

Efficiency

How efficient is Taysha Gene Therapies business performance
Taysha Gene Therapies's return on sales has shrunk by 56% QoQ and by 45% YoY
TSHA's ROE is up by 48% year-on-year
The return on invested capital has declined by 32% year-on-year and by 13% since the previous quarter
Taysha Gene Therapies's return on assets has increased by 21% YoY but it has decreased by 4.4% QoQ

Dividends

What is TSHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TSHA.

Financial health

How did Taysha Gene Therapies financials performed over time
Taysha Gene Therapies's quick ratio has surged by 163% YoY and by 14% QoQ
The current ratio has soared by 162% year-on-year and by 15% since the previous quarter
The debt is 69% less than the equity
Taysha Gene Therapies's debt to equity has shrunk by 71% YoY but it has increased by 11% QoQ
The company's equity fell by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.